ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "genomics"

  • Abstract Number: 1804 • ACR Convergence 2024

    Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
  • Abstract Number: 0904 • ACR Convergence 2024

    Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing

    Yuriy Baglaenko1, MIchelle Curtis2, Majd Al Suqri3, Ryan Agnew3, Aparna Nathan4, Hafsa Mire4, Annelise Yoo Mah-Som3, David Liu5, Gregory Newby6 and Soumya Raychaudhuri3, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Broad Institute, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Harvard Medical School, Boston, MA, 5Broad Institute, Cambridge, MA, 6Johns Hopkins, Baltimore, MD

    Background/Purpose: Genetic studies have identified thousands of individual disease-associated non-coding alleles, but identification of the causal alleles and their functions remain critical bottlenecks. Even though…
  • Abstract Number: 1810 • ACR Convergence 2024

    Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus

    Ksenia Anufrieva1, Rochelle Castillo2, Ce Gao2, Jessica Liu2, Neda Shahriari2, Kimberly Hashemi2, Dustin Taylor3, Rachael Rowley2, Elizabeth Rainone2, Avery LaChance2, Rachel Gate4, ilya Korsunsky2, Ruth Ann Vleugels5 and Kevin Wei6, 1BWH, Cambridge, MA, 2Brigham and Women's Hospital, Boston, MA, 3Vanderbilt University Medical Center, Nashville, TN, 410x Genomics, Pleasanton, CA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA

    Background/Purpose: Reliable and effective treatments for refractory cutaneous lupus erythematosus (CLE) remained elusive until the arrival of anifrolumab, a monoclonal antibody targeting the type I…
  • Abstract Number: 0022 • ACR Convergence 2024

    Transcriptomic Characterization of Knee Capsule Fibroblasts and Mesenchymal Stromal Cells Reveals an Association Between Flexion Contracture and Alterations in Immune Pathways in People with End-stage OA

    Odette Laneuville1, Daniel Stratis1, Robert Feibel2, Guy Trudel3 and T Mark Campbell4, 1University of Ottawa, Ottawa, ON, Canada, 2The Ottawa Hospital, Ottawa, ON, Canada, 3Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4Bruyère Research Institute, Ottawa, ON, Canada

    Background/Purpose: Over 10% of adults have symptomatic knee OA but no disease-modifying interventions exist. A flexion contracture (loss of extension; FC) presents in 1/3 of…
  • Abstract Number: 0907 • ACR Convergence 2024

    Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol

    Niamh Fanning1, Murray Cadzow2, Ruth Topless3, Chris Frampton4, Nicola Dalbeth5, Tony Merriman6 and Lisa Stamp4, 1University of Otago, Christchurch, New Zealand, 2University of Otago, Dunedin 9054, New Zealand, 3University of Otago, Dunedin, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5University of Auckland, Auckland, New Zealand, 6University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
  • Abstract Number: 1819 • ACR Convergence 2024

    Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis

    Ye Jin Jeong1, Gayathri Guru Murthy1, Gaochan Wang1, Tahia Rahman1 and Benjamin Korman2, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester, Rochester, NY

    Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…
  • Abstract Number: 0028 • ACR Convergence 2024

    Human Meniscus Histopathological and Transcriptomic Changes at Early and Advanced Stages of Knee Osteoarthritis

    Takuya Sakamoto1, Hannah Swahn1, Merissa Olmer1, Rachel Miller2, Anne-Marie Malfait3 and Martin Lotz1, 1Scripps Research Institute, La Jolla, CA, 2Rush University Medical Center, Chicago, IL, 3Rush University Medical Center, Division of Rheumatology, Chicago, IL

    Background/Purpose: The knee menisci are essential elements in joint biomechanics and meniscus damage is a driver of cartilage destruction and knee osteoarthritis. Meniscus damage and…
  • Abstract Number: 0909 • ACR Convergence 2024

    Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…
  • Abstract Number: 1822 • ACR Convergence 2024

    Analysis of Differential Activation of Lysophosphatidic Acid Regulated Genes in Diffuse and Limited Cutaneous Systemic Sclerosis

    Medha Kanitkar1, Philip Yee2, Stefano Rodolfi1, Kristina Clark3, Voon Ong4 and Christopher Denton5, 1University College London, London, United Kingdom, 2UCL, London, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University College London, London, England, United Kingdom, 5University College London, Northwood, United Kingdom

    Background/Purpose: Lysophosphatidic Acid (LPA) is a lipid mediator implicated in the pathogenesis of SSc and  idiopathic pulmonary fibrosis. Phase 2 clinical trials targeting this biological…
  • Abstract Number: 0063 • ACR Convergence 2024

    Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils

    Rayan Najjar1, Noga Rogel2 and Tomas Mustelin3, 1University of Washington, Seattle, 2University of Washinton, Seattle, 3University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
  • Abstract Number: 0911 • ACR Convergence 2024

    Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

    David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
  • Abstract Number: 1823 • ACR Convergence 2024

    Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts

    Zhiyun Gong1, Rezvan Parvizi2, Helen Jarnagin1, Haobin Chen3, Madeline Morrisson4, Tammara Wood5, Monique Hinchcliff6 and Michael Whitfield2, 1Dartmouth College, Lebanon, NH, 2Geisel School of Medicine at Dartmouth, Hanover, NH, 3Dartmouth, Lebanon, NH, 4Geisel School of Medicine at Dartmouth College, Hanover, NH, 5Dartmouth, Hanover, NH, 6Yale School of Medicine, Westport, CT

    Background/Purpose: Systemic Sclerosis (SSc) is a molecularly heterogeneous disease. Distinct subtypes of patients have been identified based on gene expression in skin. In this study,…
  • Abstract Number: 0037 • ACR Convergence 2023

    New Histological Approach in Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease

    Paulina Czarnota1, Rick Wilbrink2, Bhuwan Khatri1, Anna Stolarczyk1, Cherilyn Pritchett Frazee1, Chuang Li1, Caleb Marlin1, Kyle Wright3, Kandice Tessneer1, Lida Radfar4, Judith James1, Robert Scofield1, Indra Adrianto5, Astrid Rasmussen1, Joel Guthridge1, A. Darise Farris1 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Medical Center Groningen, Groningen, Netherlands, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4University of Oklahoma College of Dentistry, Oklahoma City, OK, 5Henry Ford Health, Detroit, MI

    Background/Purpose: 10X Visium spatial transcriptomics evaluates gene expression in a 50μm tile coordinate of a sectioned tissue, yielding heterogeneous cell sampling. Spatial PCA algorithm was…
  • Abstract Number: 1660 • ACR Convergence 2023

    Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways

    Mariana Correia Marques1, Zuoming Deng2, Navid Chowdhury2, Elizabeth Schmitz3, Alana Platukus4, Stephen Brooks5, Carol Lake2, Ly-Lan Bergeron2, Michelle Millwood2 and Michael Ombrello6, 1National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), St. Louis, MO, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Philadelphia, PA, 5Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD

    Background/Purpose: Still’s disease (systemic juvenile idiopathic arthritis in children, adult-onset Still’s disease in adults) is an enigmatic inflammatory condition that affects people of all ages.…
  • Abstract Number: 0039 • ACR Convergence 2023

    Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis

    Mariana Correia Marques1, Danielle Rubin1, Emily Shuldiner2, Mallika Datta1, Elizabeth Schmitz1, Alexei Grom3, Dirk Foell4, Marco Gattorno5, John Bohnsack6, Rae Yeung7, Sampath Prahalad8, Elizabeth Mellins9, Jordi Anton Lopez10, Claudio Len11, Sheila Oliveira12, Patricia Woo13, Seza Ozen14, INCHARGE Consortium1, Zuoming Deng15 and Michael Ombrello1, 1National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Department of Biology, Stanford University, Stanford, CA, 3Division of Rheumatology, Cincinnati Children`s Hospital, Cincinnati, OH, 4University Hospital Münster, Münster, Germany, 5UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 6University of Utah, Salt Lake City, UT, 7The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 8Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, 9Stanford University, Stanford, CA, 10Pediatric Rheumatology Department, Hospital Sant Joan e Deu, Barcelona University, Barcelona, Spain, 11São Paulo Federal University, São Paulo, Brazil, 12Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 13University College London, London, United Kingdom, 14Hacettepe University Medical Faculty, Ankara, Turkey, 15National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a complex inflammatory condition of childhood. It can be complicated by macrophage activation syndrome (MAS), a secondary form…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology